

18 March 2025

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

The Hydration Pharmaceuticals Company Limited (ASX:HPC): Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)

This notice is given by The Hydration Pharmaceuticals Company Limited (ASX:HPC) ACN 620 385 677 (the **Company** or **Hydralyte USA**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Act**).

Hydralyte USA has announced a pro rata, non-renounceable entitlement offer (**Entitlement Offer**) of one fully paid ordinary share (**Shares**) for every five Shares held by eligible Hydralyte USA shareholders with a registered address in Australia or New Zealand as at 7.00pm (Melbourne time) on Friday, 21 March 2025.

The Entitlement Offer is being conducted at an issue price of \$0.01 per Share (**Offer Price**) to raise up to approximately \$610,000 (before costs). A total of up to approximately 60,982,614 Shares will be issued under the Entitlement Offer (subject to rounding).

The Entitlement Offer is not underwritten.

In conjunction with the Entitlement Offer, the Company is undertaking a placement of Shares to raise \$650,000 via the issue of 65,000,000 Shares at the Offer Price (**Placement**). A total of 60 million Placement Shares (for gross proceeds of \$600,000) will be issued to Joseph Constable (or nominee) and the balance of 5 million Shares will be issued to another investor. The Shares to be issued under the Placement will not be entitled to participate in the Entitlement Offer.

The Company's 19.99% shareholder, PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (**Pure**) has committed to subscribe for its full entitlement (of 12,190,425 Shares) under the Entitlement Offer. Assuming no other subscriptions are received for the Entitlement Offer (other than Pure's), Pure will have a shareholding of approximately 19.1% after completion of the Placement and Entitlement Offer.

The Company advises that:

1. the Shares to be issued pursuant to the Entitlement Offer will be offered for issue without disclosure under Part 6D.2 of the Act;
2. this notice is being given under section 708AA(2)(f) of the Act;

3. as at the date of this notice Hydralyte USA has complied with:
- a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. sections 674 and 674A of the Act;
4. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section 708AA(7)(d) of the Act; and
5. the potential effect that the Entitlement Offer will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. At this time, the issue of Shares under the Entitlement Offer is not expected to have a material effect or consequence on the control of Hydralyte USA given:
- a. the Entitlement Offer is structured as a pro-rata issue at an offer ratio of one new Share for every five existing Shares;
 - b. the Entitlement Offer is not underwritten;
 - c. the Entitlement Offer will be undertaken in conjunction with the Placement, which will involve the issue of 65,000,000 Shares (which will not be entitled to participate in the Entitlement Offer); and
 - d. the current level of holdings of substantial holders (based on substantial holding notices that have been given to Hydralyte USA and lodged with ASX on or before the date of this notice).

Authorised for release by the Board of Directors.

ENDS

Further Information

Investors:

Victoria Nadalin
Company Secretary
hydralytecosec@cdplus.com.au
+61 425 191 695

Media:

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About Hydralyte

The Hydration Pharmaceuticals Company Limited (ASX:HPC) is an Oral Rehydration Solution company developed in Australia in 2001 producing a range of electrolyte-rich tablets, liquids and powders.

Hydralyte USA was formed in 2014 and is focussed on rapidly growing its sales footprint in the United States.

For more information on HydraLyte please visit <https://hydralyte.com.au/>

IMPORTANT INFORMATION

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.